Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
about
Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineExemestane for breast cancer prevention: a critical shift?Clinical utilities of aromatase inhibitors in breast cancerAmerican Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.Effects of the traditional Chinese medicine Yi Shen Jian Gu granules on aromatase inhibitor-associated musculoskeletal symptoms: a study protocol for a multicenter, randomized, controlled clinical trial.Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?Status of adjuvant endocrine therapy for breast cancer.Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.Is Endocrine Therapy Really Pleasant? Considerations about the Long-Term Use of Antihormonal Therapy and Its Benefit/Side Effect RatioAdjuvant Endocrine Therapy in Premenopausal PatientsAdjuvant Endocrine Therapy in Early Postmenopausal Breast CancerA prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography.Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials.Effects of age on the detection and management of breast cancer.The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuumEvaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM StudyDeclining incidence of contralateral breast cancer in the United States from 1975 to 2006Markers for the identification of late breast cancer recurrence.Extended adjuvant tamoxifen for early breast cancer: a meta-analysis.Pharmacoeconomic considerations in the treatment of breast cancer.Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for managementClinical utility of exemestane in the treatment of breast cancerComparative study on individual aromatase inhibitors on cardiovascular safety profile: a network meta-analysis.Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.Progress in endocrine approaches to the treatment and prevention of breast cancerManagement of breast cancer--Part II.Aromatase inhibition 2013: clinical state of the art and questions that remain to be solvedThe predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer.Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women.From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudyAn updated review on the efficacy of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women.The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration.Metastasis dormancy in estrogen receptor-positive breast cancer.Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients.Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer.Breast Ductal Carcinoma In Situ: A Literature Review of Adjuvant Hormonal Therapy.
P2860
Q27002430-00F937B7-3B91-40B5-BCD6-4471853D6DDEQ27028211-7CBE5449-38E7-40A6-B9D3-BD81D0AFCD1EQ28081168-5DEC2175-D636-4CB2-9B1C-F3B11C9ED0E8Q33631047-8400CFF8-A7CC-4EEC-AD8B-DC2AD8FF5D58Q33647466-EF5C1FB0-F5E5-4B31-AD13-8E64C776EC04Q33684843-0E3B48FB-D42D-4F57-A495-2DF407C18012Q33739138-CEE1E480-787A-4346-AAF7-152F44C5D934Q33793932-7FECE8F6-2854-4237-A4A2-0ECC98140C6FQ34095816-0FB209B4-2158-4418-9BF3-F0233E69C0E6Q34096277-0075EF4F-9C50-4C71-81B4-FCFEE10D669EQ34096283-1545CD71-9859-4BB2-BA11-ABFA67BBA5D3Q34116012-B1A86363-120B-4C30-A065-885EBC265999Q34233815-E9441BBC-0D21-478A-9ACB-AD3F9DDF56BAQ34477879-59BA0AE0-33F9-4833-869D-04AA956D3F04Q34592879-DB9D60E9-AB5A-4E63-9197-5B78C94805A9Q34764981-34374070-1461-4AA2-B75B-7DBC4F724C27Q34866230-FEB41FF9-BC1F-4CE2-9FAC-2BDFB2EE6319Q35018949-FE22FD03-954F-43BD-9D9F-0C30209AFA35Q35106041-B07C5F03-C0EC-43C4-9B3A-D95F9F7EC857Q35205385-9A73AF81-365B-4FCA-9D4C-C0BB5A763E84Q35558893-0907ACE4-7D19-4D2A-92DF-770937B81D7EQ35683807-06037E71-C3FF-414E-87C0-646F22292458Q36140045-51836D3E-BCE8-4293-B43E-76FC8BC79BF6Q36322870-ABEDD819-ABB4-4F6A-A25C-A0A3480A3884Q36457511-1420F99F-0317-455E-ABAB-02D257CEC8F6Q36791451-DDC1712F-07F7-4907-B243-274527A77F77Q36946008-6A70D1DF-06A1-42E6-9E97-668B98A3858EQ37081862-E0BAB072-FF7E-4C38-B98D-B39B78A845DDQ37193002-3F8AAF97-EB48-4E6C-94E5-1914226D31C8Q37213718-B0DD0A72-12BC-41C0-82B4-23A5ED4016EFQ37214217-ADD361C5-1893-4FC3-97F4-2720FF6A9E06Q37277165-0C1A37E0-7DD8-4010-BEC7-5D3760C1E42EQ37292419-C0E83C3B-4EF8-4A8B-97CA-BC81AE0A1FD0Q37366511-8569BD22-A8D8-476D-AD88-F500F1447776Q37385272-E1D7D1BA-FA94-4B80-AAA7-D700E5B8FF66Q37426886-A50A4950-0F84-4C7A-BB57-3F7BC77760F6Q37427008-0A4B5196-0198-45FE-A327-3519BB0D7340Q37444430-06B69358-ADF6-4E56-8EF0-0FF3E5DA0425Q37483932-87E91FEA-FA16-4919-B1B4-BEF247583A9CQ37527260-AF73D61A-40AE-4BB8-AA81-85A75348B574
P2860
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Extended adjuvant therapy with ...... l Cancer Study Group Trial 6a.
@en
Extended adjuvant therapy with ...... l Cancer Study Group Trial 6a.
@nl
type
label
Extended adjuvant therapy with ...... l Cancer Study Group Trial 6a.
@en
Extended adjuvant therapy with ...... l Cancer Study Group Trial 6a.
@nl
prefLabel
Extended adjuvant therapy with ...... l Cancer Study Group Trial 6a.
@en
Extended adjuvant therapy with ...... l Cancer Study Group Trial 6a.
@nl
P2093
P2860
P356
P1476
Extended adjuvant therapy with ...... l Cancer Study Group Trial 6a.
@en
P2093
Austrian Breast and Colorectal Cancer Study Group
Brigitte Mlineritsch
Christian Dadak
Christoph Tausch
Ernst Kubista
Ernst Rücklinger
Friedrich Hofbauer
Hellmut Samonigg
Karl Renner
Marianne Schmid
P2860
P304
P356
10.1093/JNCI/DJM246
P407
P577
2007-12-11T00:00:00Z